HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response N Hamdane, F Jühling, E Crouchet, H El Saghire, C Thumann, MA Oudot, ... Gastroenterology 156 (8), 2313-2329. e7, 2019 | 230 | 2019 |
Viral manipulation of STAT3: Evade, exploit, and injure AA Roca Suarez, N Van Renne, TF Baumert, J Lupberger PLoS pathogens 14 (3), e1006839, 2018 | 109 | 2018 |
Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis C virus–infected cells and liver to identify pathways associated with disease development J Lupberger, T Croonenborghs, AAR Suarez, N Van Renne, F Jühling, ... Gastroenterology 157 (2), 537-551. e9, 2019 | 107 | 2019 |
Hepatitis C virus and hepatocellular carcinoma: when the host loses its grip K Goto, AA Roca Suarez, F Wrensch, TF Baumert, J Lupberger International journal of molecular sciences 21 (9), 3057, 2020 | 79 | 2020 |
Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma F Jühling, N Hamdane, E Crouchet, S Li, H El Saghire, A Mukherji, ... Gut 70 (1), 157-169, 2021 | 72 | 2021 |
Tight junction proteins and the biology of hepatobiliary disease N Roehlen, AA Roca Suarez, H El Saghire, A Saviano, C Schuster, ... International journal of molecular sciences 21 (3), 825, 2020 | 66 | 2020 |
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis N Van Renne, AAR Suarez, FHT Duong, C Gondeau, D Calabrese, ... Gut 67 (5), 953-962, 2018 | 65 | 2018 |
HBV 2021: New therapeutic strategies against an old foe AA Roca Suarez, B Testoni, F Zoulim Liver International 41, 15-23, 2021 | 47 | 2021 |
Oncogenic signaling induced by HCV infection A Virzì, AA Roca Suarez, TF Baumert, J Lupberger Viruses 10 (10), 538, 2018 | 31 | 2018 |
Stromal and immune drivers of hepatocarcinogenesis A Saviano, N Roehlen, A Virzì, AA Roca Suarez, Y Hoshida, J Lupberger, ... Hepatocellular carcinoma: Translational precision medicine approaches, 317-331, 2019 | 15 | 2019 |
Hepatitis B virus targets lipid transport pathways to infect hepatocytes K Esser, X Cheng, JM Wettengel, J Lucifora, L Hansen-Palmus, K Austen, ... Cellular and Molecular Gastroenterology and Hepatology 16 (2), 201-221, 2023 | 11 | 2023 |
Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease AA Roca Suarez, B Testoni, TF Baumert, J Lupberger Frontiers in Immunology 11, 624034, 2021 | 11 | 2021 |
Rewiring host signaling: hepatitis C virus in liver pathogenesis A Virzì, AAR Suarez, TF Baumert, J Lupberger Cold Spring Harbor Perspectives in Medicine 10 (1), a037366, 2020 | 10 | 2020 |
Evaluation of the HBV liver reservoir with fine needle Aspirates B Testoni, AAR Suarez, A Battisti, ML Plissonnier, M Heil, T Fontanges, ... JHEP Reports 5 (10), 100841, 2023 | 7 | 2023 |
Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling AAR Suarez, TF Baumert, J Lupberger Journal of hepatology 69 (3), 564-566, 2018 | 7 | 2018 |
Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity AA Roca Suarez, E Batbold, B Bartosch, N Dashdorj, B Testoni, F Zoulim Liver International 43, 87-95, 2023 | 3 | 2023 |
Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma F Juhling, N Hamdane, E Crouchet, S Li, H El Saghire, A Mukherji, ... Gut 70 (1), 157-169, 2021 | 3 | 2021 |
TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism AAR Suarez, ML Plissonnier, X Grand, M Michelet, G Giraud, ... Gut, 2024 | 2 | 2024 |
Opportunities and challenges for hepatitis B cure AAR Suarez, F Zoulim eGastroenterology 1 (2), 2023 | 1 | 2023 |
miR-135a-5p-mediated downregulation of protein-tyrosine phosphatase delta is a candidate driver of HCV-associated hepatocarcinogenesis N Van Renne, AAR Suarez, FHT Duong, C Gondeau, D Calabrese, ... | 1 | 2016 |